RFA-DP-25-043: Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY)
Closed
This grant is closed. A newer notice from the same program is forecast: Chronic Disease Education and Awareness (CDC-RFA-DP-27-0068). Status: Expected deadline April 30, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2024.
Centers for Disease Control and Prevention - ERA offered grants of up to $700,000 to any type of organization. It expected to make about 6 awards worth $12.8 million in total. Applications closed on January 10, 2025.
From the official notice on Grants.gov, last changed December 12, 2024. Checked November 7, 2026.
- Award ceiling$700,000
- Total funding$12.8 million
- Expected awards6
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 5, 2024 |
|---|---|
| Deadline | January 10, 2025 |
| Archived by Grants.gov | February 9, 2025 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
N/A
Is this a realistic fit?
- Past Assistance Programs for Chronic Disease Prevention and Control awards averaged $1.0 million; this notice allows up to $700,000 per award.
- Most of the program's money (45% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
This NOFO aims to conduct diabetes surveillance across health system and/or health plan membership-based centers to: (1) Estimate incidence and prevalence of diabetes in youth (< 18 years) and young adults (18–44 years) in the United States. These estimates are sought by diabetes type, demographic traits, health insurance status, and geographic area to identify disparities in diabetes burden; and (2) Ascertain the prevalence of risk factors for diabetes complications, occurrence of acute and chronic diabetes complications, and use of diabetes medications among youth and young adults with diabetes. This NOFO has two (2) components to achieve the purpose of the program. Component A focuses on surveillance of diabetes among youth (< 18 years) and young adults (18–44 years). Component B serves as a Coordinating Center to provide an infrastructure for standardized approaches, analytical methods, and measures to be used for surveillance across sites. It will also develop validation protocols, serve as a data repository, and provide statistical expertise.
Who has won Assistance Programs for Chronic Disease Prevention and Control grants before
From fiscal 2021 to 2025, Assistance Programs for Chronic Disease Prevention and Control (93.945) awarded $453 million across 437 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| National Association of Chronic Disease Directors, Inc. | Georgia | 4 | $23.3 million |
| Michigan Department of Health and Human Services | Michigan | 7 | $9.5 million |
| Emory University | Georgia | 4 | $9.4 million |
| Mississippi State Department of Health | Mississippi | 4 | $9.2 million |
| Health Research, Inc. | New York | 7 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-DP-27-0068, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DP-25-043 still open?
No. It closed on January 10, 2025. A newer notice is forecast: CDC-RFA-DP-27-0068, expected deadline April 30, 2027.
Who can apply for Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY)?
Centers for Disease Control and Prevention - ERA accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY)?
Closed January 10, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $700,000 each. About $12.8 million in total across about 6 awards.
Who has won Assistance Programs for Chronic Disease Prevention and Control grants before?
The largest recipients over five fiscal years were National Association of Chronic Disease Directors, Inc., Michigan Department of Health and Human Services, Emory University. The program made 437 awards worth $453 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)